Pediatric narcolepsy

Brain and Development

Volumn 30, Issue 10, 2008, Pages 609-623

  Peterson, Paul C ^a   Husain, Aatif M ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Adolescents; Cataplexy; Children; Narcolepsy; Pediatrics

Indexed keywords

4 HYDROXYBUTYRIC ACID; AMPHETAMINE; ANTIDEPRESSANT AGENT; ARMODAFINIL; CLOMIPRAMINE; CONTRACEPTIVE AGENT; CREATINE; CREATINE PHOSPHATE; CYSTEINE ETHYL ESTER TC 99M; DESIPRAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; FLUOXETINE; GHRELIN; IMIPRAMINE; LEPTIN; LISDEXAMFETAMINE; METHAMPHETAMINE; METHYLIN ER; METHYLPHENIDATE; MODAFINIL; N ACETYLASPARTIC ACID; OREXIN; OXYBATE SODIUM; PEMOLINE; PRODRUG; PSYCHOSTIMULANT AGENT; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADOLESCENT; ADOLESCENT DISEASE; AGGRESSION; ANOREXIA; ANXIETY; ATTENTION DEFICIT DISORDER; AUTOIMMUNITY; BLOOD PRESSURE; CATAPLEXY; CEREBROSPINAL FLUID LEVEL; CHILD; CHILDHOOD DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; CONFUSION; CONTROLLED RELEASE FORMULATION; DAYTIME SOMNOLENCE; DECREASED APPETITE; DELIRIUM; DIAGNOSTIC IMAGING; DIARRHEA; DISEASE PREDISPOSITION; DIZZINESS; DRUG ABUSE; DRUG APPROVAL; DRUG CAPSULE; DRUG CLASSIFICATION; DRUG DETOXIFICATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG MEGADOSE; DRUG OVERDOSE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; EPISTAXIS; EVENING DOSAGE; FAMILY HISTORY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPERKINESIA; HYPNAGOGIC HALLUCINATION; HYPOTHALAMUS; IMMUNOTHERAPY; INSOMNIA; LIVER TOXICITY; LOW CARBOHYDRATE DIET; MORNING DOSAGE; NARCOLEPSY; NAUSEA; NERVOUSNESS; NEUROTOXICITY; NIGHT SLEEP; NIGHTMARE; NOCTURIA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PATHOPHYSIOLOGY; PERSONALITY DISORDER; PLASMAPHERESIS; PRACTICE GUIDELINE; PREVALENCE; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOSIS; RECOMMENDED DRUG DOSE; REM SLEEP; REPEATED DRUG DOSE; REVIEW; RHINITIS; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP WAKING CYCLE; SLEEP WALKING; STEVENS JOHNSON SYNDROME; STOMACH PAIN; SUDDEN DEATH; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SUSTAINED RELEASE FORMULATION; TIC; TREMOR; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

BENZHYDRYL COMPOUNDS; CATAPLEXY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DEXTROAMPHETAMINE; GHRELIN; HALLUCINATIONS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEPTIN; METHYLPHENIDATE; NARCOLEPSY; NEUROPEPTIDES; POLYSOMNOGRAPHY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP, REM; SODIUM OXYBATE;

EID: 53349109241     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.braindev.2008.02.004     Document Type: Review

References (119)

1. Overeem S., Mignot E., van Dijk J.G., and Lammers G.J. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 18 2 (2001) 78-105
2. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 50 2 Suppl. 1 (1998) S16-S22
3. Han F., Chen E., Wei H., Dong X., He Q., Ding D., et al. Childhood narcolepsy in North China. Sleep 24 3 (2001) 321-324
4. Silber M.H., Krahn L.E., Olson E.J., and Pankratz V.S. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 25 2 (2002) 197-202
5. Dauvilliers Y., Montplaisir J., Molinari N., Carlander B., Ondze B., Besset A., et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 57 11 (2001) 2029-2033
6. Nishino S., Okura M., and Mignot E. Narcolepsy: genetic predisposition and neuropharmacological mechanisms. Sleep Med Rev 4 1 (2000) 57-99
7. Maret S., and Tafti M. Genetics of narcolepsy and other major sleep disorders. Swiss Med Wkly 135 45-46 (2005) 662-665
8. Mignot E. Genetics of narcolepsy and other sleep disorders. Am J Hum Genet 60 6 (1997) 1289-1302
9. Dauvilliers Y., Maret S., Bassetti C., Carlander B., Billiard M., Touchon J., et al. A monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1. Neurology 62 11 (2004) 2137-2138
10. Mignot E., Tafti M., Dement W.C., and Grumet F.C. Narcolepsy and immunity. Adv Neuroimmunol 5 1 (1995) 23-37
11. Smith A.J., Jackson M.W., Neufing P., McEvoy R.D., and Gordon T.P. A functional autoantibody in narcolepsy. Lancet 364 9451 (2004) 2122-2124
12. Black III J.L., Krahn L.E., Pankratz V.S., and Silber M. Search for neuron-specific and nonneuron-specific antibodies in narcoleptic patients with and without HLA DQB1*0602. Sleep 25 7 (2002) 719-723
13. de Lecea L., Kilduff T.S., Peyron C., Gao X., Foye P.E., Danielson P.E., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 95 1 (1998) 322-327
14. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92 5 (1998) 1 page following 696
15. Sutcliffe J.G., and de Lecea L. The hypocretins: excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding. J Neurosci Res 62 2 (2000) 161-168
16. Ebrahim I.O., Howard R.S., Kopelman M.D., Sharief M.K., and Williams A.J. The hypocretin/orexin system. J R Soc Med 95 5 (2002) 227-230
17. Lin L., Faraco J., Li R., Kadotani H., Rogers W., Lin X., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98 3 (1999) 365-376
18. Chemelli R.M., Willie J.T., Sinton C.M., Elmquist J.K., Scammell T., Lee C., et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98 4 (1999) 437-451
19. John J., Wu M.F., and Siegel J.M. Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res Online 3 1 (2000) 23-28
20. Nishino S., Ripley B., Overeem S., Nevsimalova S., Lammers G.J., Vankova J., et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 50 3 (2001) 381-388
21. Kanbayashi T., Inoue Y., Chiba S., Aizawa R., Saito Y., Tsukamoto H., et al. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res 11 1 (2002) 91-93
22. Krahn L.E., Pankratz V.S., Oliver L., Boeve B.F., and Silber M.H. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. Sleep 25 7 (2002) 733-736
23. Kubota H., Kanbayashi T., Tanabe Y., Ito M., Takanashi J., Kohno Y., et al. Decreased cerebrospinal fluid hypocretin-1 levels near the onset of narcolepsy in 2 prepubertal children. Sleep 26 5 (2003) 555-557
24. Mignot E., Lammers G.J., Ripley B., Okun M., Nevsimalova S., Overeem S., et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 59 10 (2002) 1553-1562
25. Hartwig G., Harsh J., Ripley B., Nishino S., and Mignot E. Low cerebrospinal fluid hypocretin levels found in familial narcolepsy. Sleep Med 2 5 (2001) 451-453
26. Tanaka S., Honda Y., Inoue Y., and Honda M. Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy. Sleep 29 5 (2006) 633-638
27. Dauvilliers Y., Baumann C.R., Carlander B., Bischof M., Blatter T., Lecendreux M., et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 74 12 (2003) 1667-1673
28. Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6 9 (2000) 991-997
29. Thannickal T.C., Moore R.Y., Nienhuis R., Ramanathan L., Gulyani S., Aldrich M., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27 3 (2000) 469-474
30. Arii J., Kanbayashi T., Tanabe Y., Sawaishi Y., Kimura S., Watanabe A., et al. CSF hypocretin-1 (orexin-A) levels in childhood narcolepsy and neurologic disorders. Neurology 63 12 (2004) 2440-2442
31. Martinez-Rodriguez J.E., Lin L., Iranzo A., Genis D., Marti M.J., Santamaria J., et al. Decreased hypocretin-1 (Orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness. Sleep 26 3 (2003) 287-290
32. Kok S.W., Meinders A.E., Overeem S., Lammers G.J., Roelfsema F., Frolich M., et al. Reduction of plasma leptin levels and loss of its circadian rhythmicity in hypocretin (orexin)-deficient narcoleptic humans. J Clin Endocrinol Metab 87 2 (2002) 805-809
33. Arnulf I., Lin L., Zhang J., Russell I.J., Ripley B., Einen M., et al. CSF versus serum leptin in narcolepsy: is there an effect of hypocretin deficiency?. Sleep 29 8 (2006) 1017-1024
34. De Vriese C., and Delporte C. Influence of ghrelin on food intake and energy homeostasis. Curr Opin Clin Nutr Metab Care 10 5 (2007) 615-619
35. Sakurai T. Roles of orexins and orexin receptors in central regulation of feeding behavior and energy homeostasis. CNS Neurol Disord Drug Targets 5 3 (2006) 313-325
36. Nishino S., and Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 9 4 (2005) 269-310
37. Aldrich M.S., and Naylor M.W. Narcolepsy associated with lesions of the diencephalon. Neurology 39 11 (1989) 1505-1508
38. Clavelou P., Tournilhac M., Vidal C., Georget A.M., Picard L., and Merienne L. Narcolepsy associated with arteriovenous malformation of the diencephalon. Sleep 18 3 (1995) 202-205
39. Dalmau J., Graus F., Villarejo A., Posner J.B., Blumenthal D., Thiessen B., et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 127 Pt 8 (2004) 1831-1844
40. D'Cruz O.F., Vaughn B.V., Gold S.H., and Greenwood R.S. Symptomatic cataplexy in pontomedullary lesions. Neurology 44 11 (1994) 2189-2191
41. Lagrange A.H., Blaivas M., Gomez-Hassan D., and Malow B.A. Rasmussen's syndrome and new-onset narcolepsy, cataplexy, and epilepsy in an adult. Epilepsy Behav 4 6 (2003) 788-792
42. Malik S., Boeve B.F., Krahn L.E., and Silber M.H. Narcolepsy associated with other central nervous system disorders. Neurology 57 3 (2001) 539-541
43. Onofrj M., Curatola L., Ferracci F., and Fulgente T. Narcolepsy associated with primary temporal lobe B-cells lymphoma in a HLA DR2 negative subject. J Neurol Neurosurg Psychiatry 55 9 (1992) 852-853
44. Overeem S., Dalmau J., Bataller L., Nishino S., Mignot E., Verschuuren J., et al. Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis. Neurology 62 1 (2004) 138-140
45. Plazzi G., Parmeggiani A., Mignot E., Lin L., Scano M.C., Posar A., et al. Narcolepsy-cataplexy associated with precocious puberty. Neurology 66 10 (2006) 1577-1579
46. Kandt R.S., Emerson R.G., Singer H.S., Valle D.L., and Moser H.W. Cataplexy in variant forms of Niemann-Pick disease. Ann Neurol 12 3 (1982) 284-288
47. Smit L.S., Lammers G.J., and Catsman-Berrevoets C.E. Cataplexy leading to the diagnosis of Niemann-Pick disease type C. Pediatr Neurol 35 1 (2006) 82-84
48. Kanbayashi T., Abe M., Fujimoto S., Miyachi T., Takahashi T., Yano T., et al. Hypocretin deficiency in niemann-pick type C with cataplexy. Neuropediatrics 34 1 (2003) 52-53
49. AASM. International classification of sleep disorders. 2nd ed. Westchester, IL: American Academy of Sleep Medicine; 2005.
50. Stores G. The protean manifestations of childhood narcolepsy and their misinterpretation. Dev Med Child Neurol 48 4 (2006) 307-310
51. Scammell T.E. The neurobiology, diagnosis, and treatment of narcolepsy. Ann Neurol 53 2 (2003) 154-166
52. Thorpy M. Current concepts in the etiology, diagnosis and treatment of narcolepsy. Sleep Med 2 1 (2001) 5-17
53. Guilleminault C., and Pelayo R. Narcolepsy in children: a practical guide to its diagnosis, treatment and follow-up. Paediatr Drugs 2 1 (2000) 1-9
54. Macleod S., Ferrie C., and Zuberi S.M. Symptoms of narcolepsy in children misinterpreted as epilepsy. Epileptic Disord 7 1 (2005) 13-17
55. Okun M.L., Lin L., Pelin Z., Hong S., and Mignot E. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep 25 1 (2002) 27-35
56. Dahmen N., Bierbrauer J., and Kasten M. Increased prevalence of obesity in narcoleptic patients and relatives. Eur Arch Psychiatry Clin Neurosci 251 2 (2001) 85-89
57. Kok S.W., Overeem S., Visscher T.L., Lammers G.J., Seidell J.C., Pijl H., et al. Hypocretin deficiency in narcoleptic humans is associated with abdominal obesity. Obes Res 11 9 (2003) 1147-1154
58. Lammers G.J., Pijl H., Iestra J., Langius J.A., Buunk G., and Meinders A.E. Spontaneous food choice in narcolepsy. Sleep 19 1 (1996) 75-76
59. Schuld A., Beitinger P.A., Dalal M., Geller F., Wetter T.C., Albert E.D., et al. Increased body mass index (BMI) in male narcoleptic patients, but not in HLA-DR2-positive healthy male volunteers. Sleep Med 3 4 (2002) 335-339
60. Kotagal S., Krahn L.E., and Slocumb N. A putative link between childhood narcolepsy and obesity. Sleep Med 5 2 (2004) 147-150
61. Beuckmann C.T., and Yanagisawa M. Orexins: from neuropeptides to energy homeostasis and sleep/wake regulation. J Mol Med 80 6 (2002) 329-342
62. Crocker A., Espana R.A., Papadopoulou M., Saper C.B., Faraco J., Sakurai T., et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 65 8 (2005) 1184-1188
63. Luc M.E., Gupta A., Birnberg J.M., Reddick D., and Kohrman M.H. Characterization of symptoms of sleep disorders in children with headache. Pediatr Neurol 34 1 (2006) 7-12
64. Vandeputte M., and de Weerd A. Sleep disorders and depressive feelings: a global survey with the Beck depression scale. Sleep Med 4 4 (2003) 343-345
65. Morrish E., King M.A., Smith I.E., and Shneerson J.M. Factors associated with a delay in the diagnosis of narcolepsy. Sleep Med 5 1 (2004) 37-41
66. Ohayon M.M., Ferini-Strambi L., Plazzi G., Smirne S., and Castronovo V. Frequency of narcolepsy symptoms and other sleep disorders in narcoleptic patients and their first-degree relatives. J Sleep Res 14 4 (2005) 437-445
67. Guilleminault C., and Pelayo R. Narcolepsy in prepubertal children. Ann Neurol 43 1 (1998) 135-142
68. Dahl R.E., Holttum J., and Trubnick L. A clinical picture of child and adolescent narcolepsy. J Am Acad Child Adolesc Psychiatry 33 6 (1994) 834-841
69. Kryger M.H., Walid R., and Manfreda J. Diagnoses received by narcolepsy patients in the year prior to diagnosis by a sleep specialist. Sleep 25 1 (2002) 36-41
70. Kotagal S., Hartse K.M., and Walsh J.K. Characteristics of narcolepsy in preteenaged children. Pediatrics 85 2 (1990) 205-209
71. Carskadon M.A., Harvey K., Duke P., Anders T.F., Litt I.F., and Dement W.C. Pubertal changes in daytime sleepiness. Sleep 2 4 (1980) 453-460
72. Wise M.S. Childhood narcolepsy. Neurology 50 2 Suppl. 1 (1998) S37-S42
73. Challamel M.J., Mazzola M.E., Nevsimalova S., Cannard C., Louis J., and Revol M. Narcolepsy in children. Sleep 17 Suppl. 8 (1994) S17-S20
74. Dauvilliers Y., Gosselin A., Paquet J., Touchon J., Billiard M., and Montplaisir J. Effect of age on MSLT results in patients with narcolepsy-cataplexy. Neurology 62 1 (2004) 46-50
75. Iber C, editor. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications; 1997.
76. Kotagal S. Narcolepsy in children. Semin Pediatr Neurol 3 1 (1996) 36-43
77. Mignot E., Young T., Lin L., and Finn L. Nocturnal sleep and daytime sleepiness in normal subjects with HLA-DQB1*0602. Sleep 22 3 (1999) 347-352
78. Dauvilliers Y., Arnulf I., and Mignot E. Narcolepsy with cataplexy. Lancet 369 9560 (2007) 499-511
79. Plazzi G., Montagna P., Provini F., Bizzi A., Cohen M., and Lugaresi E. Pontine lesions in idiopathic narcolepsy. Neurology 46 5 (1996) 1250-1254
80. Bassetti C., Aldrich M.S., and Quint D.J. MRI findings in narcolepsy. Sleep 20 8 (1997) 630-631
81. Frey J.L., and Heiserman J.E. Absence of pontine lesions in narcolepsy. Neurology 48 4 (1997) 1097-1099
82. Kwen P.L., and Pullicino P. Pontine lesions in idiopathic narcolepsy. Neurology 50 2 (1998) 577-578
83. Ellis C.M., Simmons A., Lemmens G., Williams S.C., and Parkes J.D. Proton spectroscopy in the narcoleptic syndrome. Is there evidence of a brainstem lesion?. Neurology 50 2 Suppl. 1 (1998) S23-S26
84. Lodi R., Tonon C., Vignatelli L., Iotti S., Montagna P., Barbiroli B., et al. In vivo evidence of neuronal loss in the hypothalamus of narcoleptic patients. Neurology 63 8 (2004) 1513-1515
85. Joo E.Y., Hong S.B., Tae W.S., Kim J.H., Han S.J., Cho Y.W., et al. Cerebral perfusion abnormality in narcolepsy with cataplexy. Neuroimage 28 2 (2005) 410-416
86. Hong S.B., Tae W.S., and Joo E.Y. Cerebral perfusion changes during cataplexy in narcolepsy patients. Neurology 66 11 (2006) 1747-1749
87. Chabas D., Habert M.O., Maksud P., Tourbah A., Minz M., Willer J.C., et al. Functional imaging of cataplexy during status cataplecticus. Sleep 30 2 (2007) 153-156
88. Littner M., Johnson S.F., McCall W.V., Anderson W.M., Davila D., Hartse S.K., et al. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 24 4 (2001) 451-466
89. Rogers A.E., Aldrich M.S., and Lin X. A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy. Sleep 24 4 (2001) 385-391
90. Husain A.M., Yancy Jr. W.S., Carwile S.T., Miller P.P., and Westman E.C. Diet therapy for narcolepsy. Neurology 62 12 (2004) 2300-2302
91. Mitler M.M., Shafor R., Hajdukovich R., Timms R.M., and Browman C.P. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep 9 1 Pt 2 (1986) 260-264
92. Greenhill L.L., Pliszka S., Dulcan M.K., Bernet W., Arnold V., Beitchman J., et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41 Suppl. 2 (2002) 26S-49S
93. Anon. Methylphenidate. In: Clinical pharmacology. Available from: http://cpip.gsm.com/Forms/search.aspx?s=methylphenidate; 2006 [accessed December 16, 2006].
94. Anon. Amphetamine; dextroamphetamine. In: Clinical pharmacology. Available from: http://cpip.gsm.com/Forms/search.aspx?s=amphetamine; 2006 [accessed December 16, 2006].
95. Anonymous. Modafinil. In: Clinical pharmacology. Available from: http://cpip.gsm.com/Forms/search.aspx?s=mofafinil; 2006 [accessed December 16, 2006].
96. Ishizuka T., Sakamoto Y., Sakurai T., and Yamatodani A. Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett 339 2 (2003) 143-146
97. Anon. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol 1998;43(1):88-97.
98. Anon. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology 2000;54(5):1166-75.
99. Guilleminault C., and Fromherz S. Narcolepsy: diagnosis and treatment. In: Kryger M.H., Roth T., and Dement W.C. (Eds). Principles and practice of sleep medicine (2005), Elsevier, Philadelphia 780-790
100. Ivanenko A., Tauman R., and Gozal D. Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med 4 6 (2003) 579-582
101. Biederman J., Swanson J.M., Wigal S.B., Boellner S.W., Earl C.Q., and Lopez F.A. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study. J Clin Psychiatry 67 5 (2006) 727-735
102. Biederman J., Swanson J.M., Wigal S.B., Kratochvil C.J., Boellner S.W., Earl C.Q., et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 116 6 (2005) e777-e784
103. Greenhill L.L., Biederman J., Boellner S.W., Rugino T.A., Sangal R.B., Earl C.Q., et al. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45 5 (2006) 503-511
104. Anon. Sodium oxybate. In: Clinical pharmacology. Available from: http://cpip.gsm.com/Forms/search.aspx?s=sodium%20oxybate; 2006 [accessed December 16, 2006].
105. Mamelak M., Black J., Montplaisir J., and Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 27 7 (2004) 1327-1334
106. Anon. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005;1(4):391-7.
107. Black J., and Houghton W.C. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 29 7 (2006) 939-946
108. Murali H., and Kotagal S. Off-label treatment of severe childhood narcolepsy-cataplexy with sodium oxybate. Sleep 29 8 (2006) 1025-1029
109. Anon. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25(1):42-9.
110. Anon. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 2005;6(5):415-21.
111. Anon. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003;26(1):31-5.
112. Vignatelli L., D'Alessandro R., and Candelise L. Antidepressant drugs for narcolepsy. Cochrane Database Syst Rev 3 (2005) CD003724
113. Anon. Fluoxetine. In: Clinical pharmacology. Available from: http://cpip.gsm.com/Forms/search.aspx?s=fluoxetine; 2006 [accessed December 16, 2006].
114. Thorpy M.J. Sodium oxybate for the treatment of narcolepsy. Expert Opin Pharmacother 6 2 (2005) 329-335
115. Chen W., Black J., Call P., and Mignot E. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann Neurol 58 3 (2005) 489-490
116. Hecht M., Lin L., Kushida C.A., Umetsu D.T., Taheri S., Einen M., et al. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep 26 7 (2003) 809-810
117. Lecendreux M., Maret S., Bassetti C., Mouren M.C., and Tafti M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 12 4 (2003) 347-388
118. Dauvilliers Y. Follow-up of four narcolepsy patients treated with intravenous immunoglobulins. Ann Neurol 60 1 (2006) 153
119. Dauvilliers Y., Carlander B., Rivier F., Touchon J., and Tafti M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 56 6 (2004) 905-908